Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 13;22(16):8728.
doi: 10.3390/ijms22168728.

Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection

Evi B Struble  1 , Haruhiko Murata  2 , Takashi Komatsu  3 , Dorothy Scott  1
Affiliations
Review

Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection

Evi B Struble et al. Int J Mol Sci. .

Abstract

Human Cytomegalovirus (HCMV) infection is widespread and can result in severe sequelae in susceptible populations. Primary HCMV infection of naïve individuals results in life-long latency characterized by frequent and sporadic reactivations. HCMV infection elicits a robust antibody response, including neutralizing antibodies that can block the infection of susceptible cells in vitro and in vivo. Thus, antibody products and vaccines hold great promise for the prevention and treatment of HCMV, but to date, most attempts to demonstrate their safety and efficacy in clinical trials have been unsuccessful. In this review we summarize publicly available data on these products and highlight new developments and approaches that could assist in successful translation of HCMV immunotherapies.

Keywords: animal models for cytomegalovirus; cytomegalovirus prophylaxis; cytomegalovirus therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. This article reflects the views of the authors and should not be construed to represent FDA’s views or policies.

Figures

Figure 1
Figure 1
Animal models for CMV infection and disease.
See this image and copyright information in PMC

References

    1. Pediatrics A.A.O. Cytomegalovirus Infection. In: Kimberlin D.W., Long S.S., Brady M.T., Jackson M.A., editors. Red Book: 2018 Report of the Committee on Infectious Diseases. American Academy of Pediatrics; Itasca, IL, USA: 2018. pp. 310–317.
    1. About Cytomegalovirus (CMV) [(accessed on 12 August 2021)]; Available online: https://www.cdc.gov/cmv/overview.html.
    1. Cannon M.J., Schmid D.S., Hyde T.B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev. Med. Virol. 2010;20:202–213. doi: 10.1002/rmv.655. - DOI - PubMed
    1. Britt W. Manifestations of human cytomegalovirus infection: Proposed mechanisms of acute and chronic disease. Curr. Top. Microbiol. Immunol. 2008;325:417–470. doi: 10.1007/978-3-540-77349-8_23. - DOI - PubMed
    1. Limaye A.P., Babu T.M., Boeckh M. Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation. Clin. Microbiol. Rev. 2020;34:19. doi: 10.1128/CMR.00043-19. - DOI - PMC - PubMed

MeSH terms